KDR and hepatocellular carcinoma: Consistent with the anti-VEGF activity of sorafenib––and in agreement with data from trials in hepatocellular carcinoma patients of another anti-VEGFR TKI sunitinib––treatment increased the plasma concentration of VEGF and PlGF, decreased sVEGFR-2, and increased erythropoiesis [24], [32], [33].